UPDATED Apr 20, 2024
Well rounded companies, with acceptable leverage, projected to deliver an ROE north of 20% in three years.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
NOVN | CHF85.53 | -0.7% | -3.8% | CHF187.3b | CHF96.56 | PE24x | E9.5% | 3.8% | Pharmaceuticals & Biotech | ||
ROG | CHF222.10 | -1.3% | -21.0% | CHF178.8b | CHF281.61 | PE15.4x | E8.2% | 4.3% | Pharmaceuticals & Biotech | ||
ZURN | CHF448.40 | -0.7% | 4.0% | CHF64.6b | CHF459.07 | PE16.3x | E8.6% | 5.8% | Insurance | ||
SOON | CHF248.00 | -3.3% | -14.2% | CHF14.8b | CHF271.47 | PE24.6x | E10.7% | 1.9% | Healthcare | ||
SUN | CHF109.20 | -3.0% | 45.2% | CHF3.7b | CHF123.80 | PE16.1x | E8.0% | 3.4% | Capital Goods | ||
BCHN | CHF593.00 | -0.3% | 4.0% | CHF2.0b | CHF604.50 | PE25.8x | E12.8% | 2.0% | Capital Goods |